[go: up one dir, main page]

MX2016010431A - Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa. - Google Patents

Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa.

Info

Publication number
MX2016010431A
MX2016010431A MX2016010431A MX2016010431A MX2016010431A MX 2016010431 A MX2016010431 A MX 2016010431A MX 2016010431 A MX2016010431 A MX 2016010431A MX 2016010431 A MX2016010431 A MX 2016010431A MX 2016010431 A MX2016010431 A MX 2016010431A
Authority
MX
Mexico
Prior art keywords
glucosidase
alpha
preventing
conditions associated
pathological conditions
Prior art date
Application number
MX2016010431A
Other languages
English (en)
Other versions
MX365952B (es
Inventor
MAUGARD Thierry
Bordenave-Juchereau Stéphanie
Marie Piot Jean-
Ben-Henda Yesmine
Sirvent Pascal
PELTIER Sébastien
Original Assignee
Université de la Rochelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de la Rochelle filed Critical Université de la Rochelle
Publication of MX2016010431A publication Critical patent/MX2016010431A/es
Publication of MX365952B publication Critical patent/MX365952B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere a una composición que comprende al menos un péptido XAP, en el cual X representa un conjunto vacío o una valina, para su utilización en la prevención y/o el tratamiento de patologías relacionadas con la alfa-glucosidasa. La invención se refiere también a la utilización de un hidrolizado de al menos una proteína, conteniendo dicha proteína, o estando constituida por, al menos 0,05% a <5% o al menos 5% de motivos XAP, en el cual X representa un conjunto vacío o una valina, para su utilización en la prevención y/o el tratamiento de patologías relacionadas con la alfa-glucosidasa.
MX2016010431A 2014-02-18 2015-02-18 Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa. MX365952B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1451280A FR3017536B1 (fr) 2014-02-18 2014-02-18 Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
PCT/FR2015/050397 WO2015124867A1 (fr) 2014-02-18 2015-02-18 Compositions pour la prévention et/ou le traitement de pathologies liées a l'alpha-glucosidase

Publications (2)

Publication Number Publication Date
MX2016010431A true MX2016010431A (es) 2016-10-17
MX365952B MX365952B (es) 2019-06-19

Family

ID=50549145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010431A MX365952B (es) 2014-02-18 2015-02-18 Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.

Country Status (12)

Country Link
US (1) US10500245B2 (es)
EP (1) EP3107556B1 (es)
JP (3) JP6892265B2 (es)
KR (1) KR20160113736A (es)
AU (1) AU2015220649B2 (es)
CA (1) CA2944413C (es)
DK (1) DK3107556T3 (es)
ES (1) ES2732316T3 (es)
FR (1) FR3017536B1 (es)
MX (1) MX365952B (es)
NZ (1) NZ723300A (es)
WO (1) WO2015124867A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
KR102857763B1 (ko) * 2022-03-11 2025-09-12 강원대학교산학협력단 항 산화 스트레스 활성을 가지는 펩타이드, 그 제조방법 및 용도
CN114716524B (zh) 2022-04-15 2023-05-23 中国农业大学 抑制α-淀粉酶和α-葡萄糖苷酶的熟小米醇溶蛋白肽

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023087B2 (ja) * 1982-09-04 1985-06-05 工業技術院長 アンジオテンシン転換酵素阻害剤
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
KR100479968B1 (ko) * 1997-02-05 2005-03-30 에프. 호프만-라 로슈 아게 위장 리파아제 억제제의 용도
CA2819705C (en) * 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
JP2003024012A (ja) 2001-07-18 2003-01-28 National Institute Of Advanced Industrial & Technology アンジオテンシンｉ変換酵素阻害剤及び血圧降下性機能食品
US20040229934A1 (en) * 2002-10-21 2004-11-18 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
DE602004023210D1 (de) * 2003-08-01 2009-10-29 Calpis Co Ltd Biologisch nicht-abbaubares peptid, inhibitor des angiotensinumwandelnden enzyms, arzneimittel und funktionelles nahrungsmittel
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2005061529A1 (ja) * 2003-12-01 2005-07-07 Meiji Dairies Corporation アンジオテンシン変換酵素阻害ペプチド
EP1774014A2 (en) * 2004-07-12 2007-04-18 DSMIP Assets B.V. Blood pressure lowering oligopeptides
JP2006063074A (ja) * 2004-07-29 2006-03-09 Sankyo Co Ltd 糖尿病治療薬を含有する医薬組成物
JP2008509169A (ja) * 2004-08-10 2008-03-27 メディキュア・インターナショナル・インコーポレーテッド ビタミンｂ６関連化合物およびａｃｅ阻害剤を使用する組み合わせ療法ならびに糖尿病疾患の治療のためのその使用
ATE542896T1 (de) * 2004-12-23 2012-02-15 Campina Nederland Holding Bv Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung
EP1879465A1 (en) * 2005-02-09 2008-01-23 Unilever N.V. Composition comprising peptide
WO2006096769A2 (en) 2005-03-08 2006-09-14 Intermune, Inc. Use of alpha-glucosidase inhibitors to treat alphavirus infections
US20080274987A1 (en) * 2006-06-07 2008-11-06 Hej Research Institute Novel alpha glucosidase activator, pulicarside 1
US20100112170A1 (en) * 2006-11-15 2010-05-06 Sandra Petronella Barendse Edible emulsions with pgpr
CA2821861C (en) 2010-12-23 2019-09-24 Dialpha Composition comprising cinnamon extract
JP5887630B2 (ja) * 2011-08-11 2016-03-16 岡山県 ジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase

Also Published As

Publication number Publication date
CA2944413A1 (fr) 2015-08-27
WO2015124867A1 (fr) 2015-08-27
ES2732316T3 (es) 2019-11-21
KR20160113736A (ko) 2016-09-30
JP2021165290A (ja) 2021-10-14
NZ723300A (en) 2022-12-23
JP6892265B2 (ja) 2021-06-23
FR3017536B1 (fr) 2017-05-26
DK3107556T3 (da) 2019-07-22
EP3107556B1 (fr) 2019-04-10
MX365952B (es) 2019-06-19
EP3107556A1 (fr) 2016-12-28
JP2017511800A (ja) 2017-04-27
US10500245B2 (en) 2019-12-10
US20180104303A1 (en) 2018-04-19
CA2944413C (fr) 2023-05-23
FR3017536A1 (fr) 2015-08-21
BR112016019002A2 (pt) 2017-10-10
JP2019189647A (ja) 2019-10-31
AU2015220649A1 (en) 2016-08-11
AU2015220649B2 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
PH12019502279A1 (en) Cleaning compositions and uses thereof
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
HUE043341T2 (hu) Blautia hydrogenotrophica baktériumtörzset tartalmazó készítmények, hasmenés vagy székrekedés kezelésében vagy megelõzésében történõ alkalmazásra
MX389228B (es) Composiciones para tratar el cabello.
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
AU366476S (en) Bottle
EP4545544A3 (en) Modified crispr rna and modified single crispr rna and uses thereof
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
MX2017001290A (es) Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
MX2022001291A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
SG10201808278TA (en) Polishing composition and polishing method
BR112016023519A2 (pt) inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.

Legal Events

Date Code Title Description
FG Grant or registration